Why the study?
What is the prevalence of specific familial hypercholesterolemia mutations in young patients with coronary heart disease in eastern Finland?
What is the prevalence of specific familial hypercholesterolemia mutations in young patients with coronary heart disease in eastern Finland?
A PCR-based assay demonstrates a 9% prevalence of specific familial hypercholesterolemia mutations among young patients with coronary heart disease in eastern Finland.
May warrant FH mutation testing consideration in young eastern Finnish CHD patients; leaves open generalizability and outcome impact.
Two deletions of the low density lipoprotein (LDL) receptor gene account for about 90% of the mutations that cause familial hypercholesterolemia (FH) in eastern Finland. The FH-Helsinki mutation deletes exons 16, 17 and a portion of exon 18, while the FH-North Karelia allele is characterized by a deletion of seven nucleotides from exon 6 of the LDL receptor gene. We developed a DNA assay based on the use of polymerase chain reaction (PCR) which simultaneously detects both of these mutations. We have screened 90 young (< 45 years) eastern Finns with symptomatic coronary heart disease (CHD) for the presence of these FH genes. One or the other of the mutations was present in 4 out of 55 survivors of acute myocardial infarction (AMI) and 4 out of 35 patients with angina pectoris (AP), but in none of 50 healthy controls of similar age. These data show a relatively high prevalence of confirmed FH in young CHD patients (AMI and MI combined: 8/90, or 9%), and also demonstrate the feasibility of PCR techniques in diagnosis of FH among populations with enrichment of specific types of LDL receptor gene mutations.
No takes yet. Share an insight, caveat, or question.
Koivisto et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: